This page is part of the FHIR Specification (v3.3.0: R4 Ballot 2). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3
Vocabulary Work Group | Maturity Level: N/A | External | Use Context: Any |
This value set (http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution) is defined as part of HL7 v3.
Summary
Defining URL: | http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution |
Name: | v3 Code System substanceAdminSubstitution |
Definition: | Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided. |
OID: | (for OID based terminology systems) |
Source Resource | XML / JSON |
This value set is used in the following places:
This value set includes codes from the following code systems:
http://hl7.org/fhir/v3/substanceAdminSubstitution
This expansion generated 03 Apr 2018
This value set contains 9 concepts
Expansion based on http://hl7.org/fhir/v3/substanceAdminSubstitution version 2018-04-01
All codes from system http://hl7.org/fhir/v3/substanceAdminSubstitution
Lvl | Code | Display | Definition |
0 | _ActSubstanceAdminSubstitutionCode | ActSubstanceAdminSubstitutionCode | Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. |
1 | E | equivalent | Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. |
2 | EC | equivalent composition | Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril |
3 | BC | brand composition | Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven |
3 | G | generic composition | Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) |
2 | TE | therapeutic alternative | Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet |
3 | TB | therapeutic brand | Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet |
3 | TG | therapeutic generic | Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine |
1 | F | formulary | Description: This substitution was performed or is permitted based on formulary guidelines. |
1 | N | none | No substitution occurred or is permitted. |